China Medical System Holdings Limited (CMS) filed its Monthly Return for the period ended 30 June 2026, highlighting a disciplined share-buyback programme that drove a modest contraction in free-float supply while maintaining full compliance with Hong Kong listing requirements.

Key takeaways:

1. Share Repurchases • CMS executed eight on-market repurchase transactions between 1 June and 24 June 2026, buying back a total of 5.38 million ordinary shares at prices ranging from HKD 10.12 to HKD 11.09 per share. • The aggregate consideration implied by the disclosed unit prices and volumes is approximately HKD 56.85 million. • All repurchased shares were retained as treasury stock, lifting the treasury share balance to 6.40 million.

2. Issued Share Capital Movement • Issued shares (excluding treasury shares) fell to 2.43 billion as of 30 June 2026, down 5.38 million from a month earlier—equivalent to a 0.22% reduction. • Total issued shares, including treasury stock, remained unchanged at 2.44 billion, reflecting the neutral effect of repurchases held in treasury rather than cancelled.

3. Authorised Capital and Public Float • Authorised share capital stayed flat at 20.00 billion ordinary shares with a par value of USD 0.005 each, representing USD 100.00 million in authorised capital. • CMS confirmed that its public float continued to meet the Main Board’s minimum 25% requirement as at 30 June 2026.

4. Absence of Dilutive Instruments • No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or issued during the month.

The latest monthly return underscores CMS’s ongoing capital-management strategy centred on share repurchases while safeguarding regulatory compliance and maintaining a stable capital structure.